LifeSciencesPracticeDigitaldiagnostics:ApathforwardforIVDInvitrodiagnosticsplayersarebeingtestedastheirofferingsareincreasinglycommoditized.Digitaldiagnosticsoffersapathtogrowth.ThisarticleisacollaborativeeffortbyMohammadBehnam,AndreiDan,ChrisEakins,IanLyons,andGertiPellumbi,representingviewsfromMcKinsey’sLifeSciencesPractice.December2023Growthisslowinginthediagnosticsindustryincludingclinicaldecisionsupport,remotepatientashistoricallyunmetdemandisbeingmet.Thismonitoring,andpopulationhealthmanagement,areisparticularlytrueinareassuchashematology,projectedtooutgrowthecorediagnosticsmarketclinicalchemistry,andimmunoassays.Overthepastoverthenextseveralyears(Exhibit1).Ofcourse,thisdecade,forinstance,thepriceofnext-generationvalueisnotonlyforIVDplayerstocapture.Othersequencinghasdecreasedroughly100-fold.1Attheplayers,suchashealthtechanddatacompanies,sametime,newlower-costplayersareenteringthearealsoeyeingthespace.However,asdevelopersmarket,andtheconsolidationofhealthsystemsandofdata-generatingequipmentarealreadygrouppurchasingorganizationsisdrivingdownnetbeingintegratedintokeyclinicalworkflows,IVDprices(seesidebar,“Currenttrendsindiagnostics”).2companieshavearighttoplayandcouldpotentiallyThus,forinvitrodiagnostics(IVD)players,simplyusetheirpositiontobecomekeystakeholdersinthehavingatestisnolongersufficient.It’s...
发表评论取消回复